Cybin Inc. Prices $50M Underwritten Offering to Fund Clinical Trials
HELP sits 39% above its 52-week low of $3.76 on elevated volume (3.1× avg).
Summary
Cybin Inc. announced the pricing of a $50 million underwritten offering at $4.85 per share, providing critical funding for its HLP003 Phase 3 clinical trial and other drug development programs, despite significant shareholder dilution.
Key Events · Financing and Capital Events · HELP
-
Underwritten Offering Priced
Cybin Inc. finalized an underwritten offering of 10,309,280 common shares at an offering price of US$4.85 per share, raising aggregate gross proceeds of US$50 million. The offering is expected to close on June 25, 2026.
-
Substantial Share Dilution
The offering will result in significant dilution for existing shareholders, with approximately 10.3 million new shares being issued against a current outstanding share count of approximately 51.7 million shares.
-
Funding for Clinical Pipeline
The net proceeds from the offering are intended to progress the company's HLP003 Phase 3 clinical trial for Major Depressive Disorder, HLP004 for Generalized Anxiety Disorder, HLP005 programs, and for general working capital.
-
Phase 3 Trial Progress Update
The company also reported that its HLP003 Phase 3 clinical trial for Major Depressive Disorder has surpassed 86% enrollment, with topline data expected in the fourth quarter of 2026. This update was previously announced.
Analysis · HELP · Life Sciences
This filing finalizes the terms and pricing of a significant $50 million underwritten offering, initiated on June 23, 2026. The offering is priced at a discount to the current market price and will result in substantial dilution for existing shareholders. However, this capital infusion is crucial for advancing the company's HLP003 Phase 3 clinical trial for Major Depressive Disorder, which recently surpassed 86% enrollment, as well as other key pipeline programs. This funding provides essential runway for a clinical-stage biotech to progress its drug development.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 37.2% of the 999 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.80%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HELP was trading at $5.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $3.76 to $9.83. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.